COMPOUND PROFILE / PEPTIDES & ANALOGUES
LL-37.
Research draftLL-37 is an endogenous antimicrobial host-defence peptide.
Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.
Targeted source and identity review, not a systematic review or complete regulatory audit.
Overview
LL-37 is an endogenous antimicrobial host-defence peptide.
Mechanism
It interacts with microbes and immune signalling in context-dependent ways.
Human research
Limited route-specific clinical work exists, including an oral trial; this does not validate systemic injection.
Preclinical & other research
Extensive laboratory research includes antimicrobial and inflammatory models.
Safety & unknowns
Immune activity can be harmful as well as beneficial; systemic safety remains insufficiently characterised.
Regulatory status
No broad antimicrobial or immune-enhancement authorisation is established here.
Reported use & evidence
The supplied LL-37 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.
Sources & references
Follow the cited records and registered research. Profiles remain research drafts.